Actinium Ac 225 DOTATATE RYZ101

Small molecule

Actinium Ac 225 DOTATATE RYZ101 is one of 7 small molecule programs targeting Intracranial Meningioma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intracranial MeningiomaActive, not recruiting

Intracranial MeningiomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Intracranial Meningioma

#DrugCompanyPhaseTrials

Erivedge

Roche

Phase 2

1 2

Truqap

AstraZeneca

Phase 2

1 3

Verzenio

Eli Lilly

Phase 2

1 4

Afinitor

Novartis

Phase 2

1 5

Avastin

BBio-Thera Solutions

Phase 2

1 6

FAK Inhibitor GSK2256098

AAlliance for Clinical Trials in Oncology

Phase 2

1 7

Actinium Ac 225 DOTATATE RYZ101

JJoshua Palmer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Intracranial Meningioma

NCT07150806

Clinical

Trials by Indication[1]

Intracranial Meningioma1 trial

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Recruiting·JJoshua Palmer·Phase 1/2·NCT07150806·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Actinium Ac 225 DOTATATE RYZ101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Actinium Ac 225 DOTATATE RYZ101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Actinium Ac 225 DOTATATE RYZ101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Joshua Palmer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: JJoshua Palmer

Actinium Ac 225 DOTATATE RYZ101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Intracranial Meningioma1 trial

References

Drug Info

Quick Facts

Related News